$CNAT new volume breakout candles Nasdaq $3.15
Post# of 60
Posted On: 04/06/2016 5:13:12 PM
$CNAT new volume breakout candles
Nasdaq $3.15
Website
Shares Outstanding: 20.81M
Float: 14.69M
% Held by Insiders: 26.83%
% Held by Institutions: 34.40%
Shares Short (as of Mar 15, 2016): 814.16K
Short Ratio (as of Mar 15, 2016): 6.17
Short % of Float (as of Mar 15, 2016): 5.59%
Shares Short (prior month): 877.77K
Headlines
Company Profile-Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its products include Emricasan, an orally active pan-caspase protease inhibitor, which is in Phase 2 clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post liver transplant clearance of hepatitis C virus infection with sustained viral response, non-alcoholic steatohepatitis, and nonalcoholic fatty liver disease. The company was founded in 2005 and is headquartered in San Diego, California.
Nasdaq $3.15
Website
Shares Outstanding: 20.81M
Float: 14.69M
% Held by Insiders: 26.83%
% Held by Institutions: 34.40%
Shares Short (as of Mar 15, 2016): 814.16K
Short Ratio (as of Mar 15, 2016): 6.17
Short % of Float (as of Mar 15, 2016): 5.59%
Shares Short (prior month): 877.77K
Headlines
Company Profile-Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its products include Emricasan, an orally active pan-caspase protease inhibitor, which is in Phase 2 clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post liver transplant clearance of hepatitis C virus infection with sustained viral response, non-alcoholic steatohepatitis, and nonalcoholic fatty liver disease. The company was founded in 2005 and is headquartered in San Diego, California.
(0)
(0)Histogen Inc. (HSTO) Stock Research Links
Scroll down for more posts ▼